• Je něco špatně v tomto záznamu ?

Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe

J. Rees, S. Foley, M. Huang, J. Rosa Arias, R. Skoumal, C. Walters, Y. Yavuz, S. De Wachter,

. 2019 ; 38 (3) : 981-989. [pub] 20190222

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006567

AIM: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed-dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α-blocker), on health-related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in routine clinical practice. METHODS: EUROPA was a noninterventional study of men with LUTS/BPH not responding to monotherapy who were prescribed Vesomni in routine clinical practice. Data were collected retrospectively (1 year) and prospectively (1 year). Assessments were performed at baseline, weeks 4 to 8, weeks 9 to 18 (optional), weeks 19 to 39 (optional), and Weeks 40 to 52. The primary endpoint was change from baseline in HRQoL, as assessed by the Overactive Bladder Questionnaire (OAB-q) symptom bother subscale score. Change from baseline in OAB-q total and coping, sleep, and social interaction subscale scores, treatment satisfaction-visual analog scale (TS-VAS), International Prostate Symptom Score (IPSS), and European Quality of Life 5-Dimension-5-Level (EQ-5D-5L) questionnaire were also evaluated. RESULTS: Five hundred and eighty-nine patients were enrolled. The mean changes in adjusted mean (95% confidence interval [CI]) OAB-q symptom bother subscale scores were -16.40 (-24.31, -8.49) at weeks 4 to 8 and -19.59 (-28.26, -10.92) at weeks 40 to 52; at weeks 40 to 52, changes were clinically meaningful in 84.6% of patients. Adjusted mean (95% CI) change from baseline to weeks 40 to 52 were 15.02 (7.35, 22.69), 19.37 (10.86, 27.89), 18.65 (7.44, 29.86), 9.85 (3.90, 15.81), and 16.09 (9.07, 23.11) for concern, coping, sleep, social interaction, and total, respectively. TS-VAS, IPSS, and EQ-5D-5L all improved, and treatment persistence at weeks 40 to 52 was 77.1%. Urinary retention was reported in four (0.7%) patients. CONCLUSIONS: Vesomni was well-tolerated and improved HRQoL and treatment satisfaction in patients with LUTS/BPH.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006567
003      
CZ-PrNML
005      
20200525105919.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/nau.23944 $2 doi
035    __
$a (PubMed)30801782
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rees, Jonathan $u Department of Brockway Medical Centre, Tyntesfield Medical Group, Bristol, UK.
245    10
$a Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe / $c J. Rees, S. Foley, M. Huang, J. Rosa Arias, R. Skoumal, C. Walters, Y. Yavuz, S. De Wachter,
520    9_
$a AIM: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed-dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α-blocker), on health-related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in routine clinical practice. METHODS: EUROPA was a noninterventional study of men with LUTS/BPH not responding to monotherapy who were prescribed Vesomni in routine clinical practice. Data were collected retrospectively (1 year) and prospectively (1 year). Assessments were performed at baseline, weeks 4 to 8, weeks 9 to 18 (optional), weeks 19 to 39 (optional), and Weeks 40 to 52. The primary endpoint was change from baseline in HRQoL, as assessed by the Overactive Bladder Questionnaire (OAB-q) symptom bother subscale score. Change from baseline in OAB-q total and coping, sleep, and social interaction subscale scores, treatment satisfaction-visual analog scale (TS-VAS), International Prostate Symptom Score (IPSS), and European Quality of Life 5-Dimension-5-Level (EQ-5D-5L) questionnaire were also evaluated. RESULTS: Five hundred and eighty-nine patients were enrolled. The mean changes in adjusted mean (95% confidence interval [CI]) OAB-q symptom bother subscale scores were -16.40 (-24.31, -8.49) at weeks 4 to 8 and -19.59 (-28.26, -10.92) at weeks 40 to 52; at weeks 40 to 52, changes were clinically meaningful in 84.6% of patients. Adjusted mean (95% CI) change from baseline to weeks 40 to 52 were 15.02 (7.35, 22.69), 19.37 (10.86, 27.89), 18.65 (7.44, 29.86), 9.85 (3.90, 15.81), and 16.09 (9.07, 23.11) for concern, coping, sleep, social interaction, and total, respectively. TS-VAS, IPSS, and EQ-5D-5L all improved, and treatment persistence at weeks 40 to 52 was 77.1%. Urinary retention was reported in four (0.7%) patients. CONCLUSIONS: Vesomni was well-tolerated and improved HRQoL and treatment satisfaction in patients with LUTS/BPH.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a lidé $7 D006801
650    _2
$a symptomy dolních močových cest $x komplikace $x farmakoterapie $x psychologie $7 D059411
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a spokojenost pacientů $7 D017060
650    _2
$a prospektivní studie $7 D011446
650    _2
$a hyperplazie prostaty $x komplikace $7 D011470
650    _2
$a kvalita života $7 D011788
650    _2
$a solifenacin sukcinát $x terapeutické užití $7 D000069464
650    _2
$a sulfonamidy $x terapeutické užití $7 D013449
650    _2
$a tamsulosin $x terapeutické užití $7 D000077409
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hyperaktivní močový měchýř $x farmakoterapie $x psychologie $7 D053201
650    _2
$a urologické látky $x terapeutické užití $7 D064804
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Foley, Steve $u Department of Urology, Royal Berkshire Hospital, Reading, RG 1 5AN, Berkshire, UK.
700    1_
$a Huang, Moses $u Department of European Medical Affairs, Astellas Pharma Europe Ltd., Chertsey, UK.
700    1_
$a Rosa Arias, José $u Department of Urology, Hospital Santiago Apóstol, Miranda de Ebro-Burgos, Spain.
700    1_
$a Skoumal, René $u Department of Urology, Urocentrum Brno, Brno, Czechia.
700    1_
$a Walters, Carien $u Department of Medical and Clinical Operations EMEA, Astellas Pharma Europe Ltd., Chertsey, UK.
700    1_
$a Yavuz, Yalcin $u Department of Data Science, Formerly with Astellas Pharma Global Development, Leiden, The Netherlands.
700    1_
$a De Wachter, Stefan $u Department of Urology, University Hospital Antwerpen, Edegem, Belgium.
773    0_
$w MED00003515 $t Neurourology and urodynamics $x 1520-6777 $g Roč. 38, č. 3 (2019), s. 981-989
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30801782 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525105919 $b ABA008
999    __
$a ok $b bmc $g 1525425 $s 1096623
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 3 $d 981-989 $e 20190222 $i 1520-6777 $m Neurourology and urodynamics $n Neurol. urodyn. (Print) $x MED00003515
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace